Main Text {#sec1}
=========

Neuropathic pain (NeuP) arises as a consequence of a lesion or disease of the somatosensory nervous system ([@bib98]). It is common, affecting 7%--10% of the general population, and its prevalence is projected to increase with the aging population, diabetes epidemic, and improved cancer survival ([@bib186]). Unfortunately, current drug treatments for NeuP are inadequate due to both poor efficacy and tolerability ([@bib71]). NeuP is also associated with a high level of disability and a large socio-economic cost: the global burden of disease survey showed that chronic pain is the third most important cause of disability-adjusted life-years worldwide ([@bib78], [@bib153]). The current opioid epidemic exemplifies the problems associated with long term treatment of NeuP and the need for alternative non-addictive therapeutics ([@bib99]). We do not yet have a full understanding of the drivers of NeuP and the extent to which they depend on the specific underlying etiology. For example, are the factors that precipitate NeuP in traumatic nerve injury and post-herpetic neuralgia the same? Nor do we have a full explanation as to why, following the same insult, some patients develop NeuP and others do not. Why for instance do only 30%--50% of diabetic polyneuropathy patients develop NeuP ([@bib66])? Differences here are likely to depend on a complex interaction between environmental and genetic factors that alter both the vulnerability and resilience of the somatosensory nervous system. A better understanding of the genetic architecture of NeuP will therefore provide fundamental insights into disease pathophysiology, help us understand inter-individual variation in NeuP, and reveal new drug targets.

Despite great efforts, the development of new and effective treatments for NeuP has proved difficult, with a number of promising pharmacological targets identified in preclinical studies failing to achieve clinical efficacy ([@bib145]). The reasons for this are complex, spanning the whole process of drug development but broadly falling into two categories: the sensitivity of clinical trials for NeuP therapies due to the subjectivity of pain reporting, the placebo effect and case mix ([@bib73]) and the ability of animal models to predict clinical efficacy ([@bib145]).

There have been major advances in gene sequencing technology and the informatics required to deal with large data volumes. These are now being applied at a national scale to health services, for instance, the sequencing of 100,000 whole genomes by the National Health Service (NHS) in the UK ([@bib160]). The sensory phenotyping of NeuP has become more precise and can now be combined with large clinical and research cohorts such as the UK-Biobank of 500,000 people ([@bib173]). The HEAL initiative in the USA (<https://heal.nih.gov>) is also collecting pain outcome measures and genetic data ([@bib189]) providing opportunities to create large-scale international consortia ([@bib144]). Complementary advances in mouse genetics have improved the precision of basic research into the discovery of pain mechanisms. The speed with which we can manipulate the genome of model organisms such as the fruit fly and mouse, or even human sensory neurons derived from stem cells, means we can rapidly interrogate gene function once genes of interest are identified. Given the multi-disciplinary expertise needed to make full use of these resources, we organized a joint satellite meeting of the NeuP and Genetics Special Interest Groups (SIGs) of the International Association for the Study of Pain (IASP) at The Jackson Laboratory, Bar Harbor, ME (September 10 and 11, 2018), which inspired many of the ideas presented in this review.

Assessment of NeuP in Patients {#sec1.1}
------------------------------

The past decade has seen great improvements in the techniques used to define the sensory profile of NeuP patients ([Figure 1](#fig1){ref-type="fig"}). These include questionnaires to assess pain quality, psychophysical tools to assess sensory perception, and alteration of experimental pain through conditioned pain modulation (CPM). These questionnaires e.g., NPSI, DN4, painDETECT, and LANSS ([@bib19]) incorporate descriptors of sensory symptoms to generate a score that helps predict whether the pain is likely to be neuropathic or not, and to characterize distinct dimensions of NeuP. Psychophysical tools to test the function of the somatosensory nervous system have benefited from standardization of quantitative sensory testing (QST) protocols. This consistency of reporting enables the generation of large cohorts of patients from different centers, so enhancing statistical power ([@bib154]). Conditioned pain modulation are dynamic psychophysical protocols that aim to explore an individual's descending pain modulatory system, although the complexity of the protocols and the variability in the size and stability of the response remains a challenge ([@bib101]). Deployment of a combination of the above techniques now enables the stratification of NeuP patients according to sensory profile, providing a much richer dataset than simply classifying patients according to etiology (e.g., polyneuropathy versus post-herpetic neuralgia) and enabling for selection of patients with specific phenotypes to empower clinical trials ([@bib9]). There have also been significant advances in the development of biomarkers which assess neurobiological processes underlying pain but are not dependent on patient report, such as neurophysiology (microneurography and evoked potentials) and neuro-imaging ([@bib182]). When different biomarkers are used in combination they can become objective indicators with adequate specificity and sensitivity to aid diagnosis and prognosis ([@bib182]).Figure 1A Comparison of the Genetic Investigation and Functional Analysis of NeuP in Human and Animal ModelsThe study of NeuP in humans has the obvious advantage of verbal feedback of the individual's subjective experience. The development of relatively non-invasive neurophysiological techniques has allowed us to further probe for diagnostic and functional biomarkers in NeuP patients. The house mouse (*Mus musculus*) and fruit fly (*Drosophila melanogaster*) are genetically modifiable organisms commonly used in studies of nociception and pain processing. High-throughput genetic and phenotypic analysis (e.g., nociception) can be achieved in flies, as well as fish and worms, whereas complex behavioral traits such as cognitive affect can be assessed in rodents. Appreciation of plasticity in the fly nervous system has led to the application of several injury and chemically induced neuropathy models to this organism ([@bib103]). Adult flies are also capable of learned conditioning to thermal stimuli such that they subsequently avoid that area of the chamber even in the absence of heat ([@bib197]). Mutants displaying spontaneous avoidance behavior that mimics the stimulus-elicited avoidance response in wild-type larvae remain to be investigated as a possible measure of ongoing aversive sensation ([@bib89]). Abbreviations: CCI, chronic constriction injury; CRISPR/Cas9, clustered regularly interspaced palindromic repeats/CRISPR-associated protein-9 nuclease; DN4, Neuropathic Pain Diagnostic Questionnaire; EMS, ethyl methanesulfonate; ENU, N-ethyl-N-nitrosourea; GWAS, whole-genome association study; LANNS, Leeds Assessment of Neuropathic Symptoms and Signs; NPSI, neuropathic pain symptom inventory; QST, quantitative sensory testing; SNI, spared nerve injury; SNL, spinal nerve ligation; TALENs, transcription activator-like effector nucleases); TMP/UV, trimethylpsoralen/ultra violet; ZFN, zinc-finger nuclease.

Combining such sensory phenotyping and biomarkers with genetics should provide significant added value in understanding the pathophysiology of NeuP and be of clinical relevance in terms of diagnosis, prognosis, and treatment choice. Their use will depend on the cohort being studied. For example, questionnaires can be applied at population level, while QST is only feasible in patients attending specialized services. However, standardization of QST protocols has enabled increased cohort size. These methods have associated gene variants with particular aspects of the NeuP sensory phenotype, such as paradoxical heat sensation (the perception of warmth/heat as the skin is cooled) ([@bib21]). Brain imaging is now also being used at the population level; for instance, UK-Biobank plans to image 100,000 predominantly healthy genome-sequenced individuals, who will then be followed longitudinally. An initial analysis has already shown that structural and functional brain imaging phenotypes are heritable ([@bib61]), with over 100 genomic regions showing associations with imaging phenotypes. Although such imaging studies are not undertaken using an experimental pain model, clinical pain data *are* being collected, and they do begin to provide insight into the genetic basis of brain structure/connectivity. This will help inform on the brain's response to disease and explore the hypothesis that brain circuitry confers resilience or vulnerability to NeuP ([@bib56]).

The Genetic Epidemiology of NeuP {#sec1.2}
--------------------------------

Genetic epidemiology---the study of the role genetic factors play in determining health-related states or events in a population---is a useful tool to help understand NeuP as it can reveal genetic variants associated with disease risk ([@bib119]). Genetic epidemiology studies of NeuP have presented a number of challenges ([Figure 2](#fig2){ref-type="fig"}). The first is sample size. In order to detect genetic associations, particularly those of small effect size, a study must have sufficient statistical power. In genome-wide association studies (GWASs) of other conditions, well-powered cohorts usually exceed ten thousand participants. A recent example of this is in type 2 diabetes where one study used a cohort of 74,124 cases and 824,006 controls by combining genetic data from 32 different studies. This enabled the authors to identify 243 loci that reached significance (p \< 5 × 10^−8^) and accounted for approximately 18% of the variance in risk and around a half of the estimated overall heritability ([@bib117]). To date, genetic studies of NeuP have typically analyzed cohorts with fewer than a thousand cases, which has resulted in only suggestive associations ([@bib88]). One reason that genetic studies in NeuP lack sufficient sample sizes is the costs associated with recruiting, adequately phenotyping, and genotyping the cohort. A solution to this problem lies in cross-institution collaboration where cohorts can be combined and meta-analyses can be conducted to boost sample size and power. Combining such cohorts requires harmonization between them, which brings us onto the next challenge. A recent systematic review of genetic studies of NeuP identified 29 studies, with no two studies using the same NeuP case definition ([@bib188]). This has made it difficult to compare the genetic variants and their effect size estimates across studies, and to combine data to conduct meta-analyses ([@bib63]). A robust phenotypic definition of NeuP is needed, that all researchers adhere to, in order to accurately identify cases and controls. A consensus definition on NeuP has led to international harmony on clinical NeuP assessment, but these methods are not necessarily amenable to large populations ([@bib72]). In a research setting, a good NeuP definition and classification into specific subgroups should be valid (identifying people with and without NeuP), feasible to use (in terms of the study time, ethics, and cost), accurate and precise (having high sensitivity and specificity), and, above all, reproducible. To address this issue, NeuP SIG have published a set of recommendations for phenotyping NeuP ([@bib187]). The NeuP Phenotyping by International Consensus (NeuroPPIC) guidelines provide a set of entry-level criteria with which to assess participants for NeuP, including use of a validated NeuP screening tool, anatomical distribution of pain using a body chart or checklist, and pain history (including intensity, duration, underlying etiology, and demographics). However, preliminary analysis of the feasibility of NeuroPPIC suggests that it may currently be overly stringent, meaning that larger cohorts than are currently available would be required to produce a sample size that has adequate statistical power (unpublished data). This demonstrates the trade-off between feasibility and validity of phenotyping criteria. A further complication is the fact that the standard validated NeuP screening tools do not always agree. A study of the agreement of the Self-report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) ([@bib18]) and Douleur Neuropathique 4 Questions (DN4) ([@bib26]) screening tools in 45 patients with low back pain or related leg pain revealed only a moderate correlation, albeit statistically significant ([@bib192]).Figure 2The Challenges of Conducting Genome-wide Association Studies in NeuP

Despite these shortcomings, a number of molecular, candidate-gene, and genome-wide studies have been conducted in humans that are comprehensively summarized in a recent systematic review ([@bib188]). Investigations eligible for inclusion were those that examined genetic variants in people with NeuP compared to people without NeuP. These studies identified 28 genes that show study-wide association with the presence of NeuP. Together, these genes provide important clues as to the biological mechanisms involved in the onset and persistence of NeuP ([Figure 3](#fig3){ref-type="fig"}). The association of variants in *COMT*, *OPRM1*, *SCN9A*, *SLC6A4*, and *CACNG2* demonstrates the involvement of neurotransmission. Major histocompatibility complex and cytokine genes including *HLA*-*A*, *HLA*-*B*, *HLA*-*DQB1*, *HLA*-*DRB1*, *B2M*, *IL6*, *IL1R2*, *IL10*, and *TNF*-*a* represent the immune response pathway, and it is interesting to note that these genes are also associated with underlying diabetic neuropathy and post-herpetic neuralgia etiologies. Finally the identification of genes involved in iron metabolism including *ACO1*, *BMP6*, *FXN*, *TF*, *CP*, *TFRC*, *SLC11A2*, and *GCH1* illustrates the role of metabolic pathways in neuropathic sensory dysfunction. Of the genes that were identified in candidate gene-studies, variants in HLA genes, *COMT*, *OPRM1*, *TNF-a*, *IL6*, and *GCH1* were found to have an association with NeuP in more than one study ([@bib188]). While other genes including *SCN9A* have been associated with pain intensity in neuropathy ([@bib151]), only the *HLA* genes (*A*, *B*, and *DRB1*) have been replicated consistently as associated with the presence or absence of NeuP in the same etiology (post herpetic neuralgia) ([@bib161], [@bib142], [@bib174]). In addition, polymorphisms in *GCH1* that were originally identified as risk factors in persistent lumbar root pain ([@bib180]) have been associated with NeuP in a further two different etiologies (HIV-induced sensory neuropathy and persistent postsurgical pain) suggesting that the recently discovered role of *GCH1* in energy metabolism may potentially lie at a key intersection in NeuP development ([@bib48]). Furthermore, three GWASs of NeuP have been conducted to date. Two used a prescription-based phenotype for NeuP (572 and 961 cases) ([@bib128], [@bib129]) and another used knee pain cohorts screened for NeuP using the painDETECT questionnaire (331 cases) ([@bib193]). However, none of the loci identified by these studies (*GFRA2*, *ZSCAN20*-*TLR12P*, *HMGB1P46*, or *PRKCA*) reached genome-wide significance, again highlighting the importance of sample size and phenotype harmonization. Such factors are currently being addressed by the DOLORisk study (<http://dolorisk.eu/>) ([@bib144]), a European consortium that aims to identify risk factors for NeuP. For this study, a core group of questionnaires has been developed, based on the NeuroPPIC guidelines. This has been used to phenotype two Scottish cohorts covering 33,000 individuals. Furthermore, consenting participants of the UK Biobank cohort are currently being re-phenotyped for pain using the DN4 questionnaire (originally ∼500,000). Although the survey is still being completed, it is expected that responses will be received from around 175,000 participants. Assuming a NeuP prevalence of 7% ([@bib186]), which is at the lower end of estimations, it is predicted that the number of people with NeuP will be over 12,000, providing the power to identify novel genetic variants.Figure 3A Venn Diagram of Genes Reaching Study Specific or Suggestive Significance in Human Candidate Gene and Genome-wide Studies So Far in NeuP and the Overlap of Biological PathwaysThese genes have been summarized in a recent systematic review of NeuP by [@bib188], where the inclusion criteria were any study analyzing genetic variants in people with NeuP compared to people without NeuP. The number of genes and our understanding of their contribution within these pathways, in the context of NeuP, is likely to change as more studies are published.

Requiring such a stringent p value threshold (p \< 5 × 10^−8^) to deal with multiple testing and protect against type I error (false association) is in tension with the greater chance of a type II error (overlooked associated genes). Pathway or gene set enrichment analysis that combines the association statistics of genes co-involved in defined signaling pathways can be one way to deal with this issue. This can be informative on the basis of aggregate data from multiple SNPs that show suggestive association but which individually do not reach the nominal threshold of 5 × 10^−8^ ([@bib114], [@bib143]). Another is more complex statistical approaches, and with the advent of machine learning such methods should become more common ([@bib113], [@bib54]). Large-scale genome or exome sequencing will likely become increasingly relevant in these cohorts as the price of these methods fall. As the sample sizes used in GWASs steadily increase, it is predicted that single variants will account for between one- and two-thirds of the heritability of most complex traits ([@bib175]). While it is unlikely GWAS approaches will be able to explain all of NeuP heritability, it currently represents the most powerful approach available to identify genetic risk and thus targets for new therapies.

Further insights into the genetics of NeuP are being provided by the recently created Human Pain Genetics Database (HPGdb; <http://humanpaingenetics.org/hpgdb>) ([@bib127]). The HPGdb provides a central and up-to-date resource listing all genetic variants associated with pain and related phenotypes, including NeuP.

How Can Genetic Epidemiology Be Used to Benefit Patients? {#sec1.3}
---------------------------------------------------------

With more complex analysis of multiple genetic variants, attention inevitably turns to how these variants can be used to benefit patients and improve quality of life. One route being investigated is polygenic risk scores (PRSs). Polygenic risk scores quantify an individual's overall likelihood of developing a given disorder by assessing how many known risk alleles that person has and weighting them according to their estimated effect size from GWASs. This approach has identified a significant proportion of people that have more than three times the risk of developing a disorder, for instance, defining 8% of the population at risk of coronary artery disease, 20 times more than could be identified by screening for rare monogenic disorders ([@bib102]). Although there has been preliminary research into polygenic risk scores and pain, this has yet to be explored specifically in NeuP due to the lack of highly powered GWAS studies ([@bib125]).

Currently, front-line medications used to treat NeuP, including gabapentinoids, tricyclic antidepressants, and serotonin-noradrenaline reuptake inhibitors, achieve only a 30%--50% reduction in pain severity, in 30% of patients ([@bib71]). In order to improve clinical outcomes for existing medications and in common with patient association studies, it has been suggested that patients should be categorized according to their QST profiles ([@bib75]). Furthermore, genetic variants could help explain variation in treatment response and toxicity of different drugs (pharmacogenetics). For this, variants need to be sufficiently common in the population and confer a clinically meaningful difference in treatment response. Again detecting these variants relies on large discovery cohorts, with sufficient statistical power. Because of this difficulty, very few pharmacogenetics studies have been conducted in NeuP to date ([@bib28], [@bib39]). Sensory phenotype stratification, together with classifying patients depending on genetic risk, has the potential to lead to personalized medicine to determine the best course for treatment.

Genetic Variants in Ion Channels: From Rare Mendelian to Common NeuP Disorders {#sec1.4}
------------------------------------------------------------------------------

The discovery and investigation of genetic variants in ion channels is one of the best examples as to how human genetics can have a profound influence on the pain field. Hyper-excitability of the somatosensory nervous system underpins the sensory dysfunction of NeuP and is driven by the altered activity of ion channels. Mutations in ion channels have been found to underlie rare inherited painful disorders ([@bib67], [@bib199]), and variants in the same genes have recently been associated with more common NeuP states ([@bib64], [@bib23]).

Most of the genetic variants that alter pain transmission have been found in three voltage-gated sodium channels: Na~V~1.7, Na~V~1.8, and Na~V~1.9. All three demonstrate highly enriched expression in pain circuits, particularly in nociceptors, and have important functions in the initiation and proper firing of action potentials ([@bib58], [@bib1], [@bib20]). Familial studies of rare variants with high penetrance that cause NeuP allow us to understand the contributions these channels make to primary afferent excitability. Gain-of-function mutations in *SCN9A* (the gene encoding Na~V~1.7) lead to inherited erythromelalgia (IEM; pain and erythema of the hands and feet) ([@bib199]) or paroxysmal extreme pain disorder (PEPD; paroxysmal pain and erythema of the sacrum and mandible) ([@bib67]), while loss-of-function mutations lead to pain insensitivity ([@bib47]). The biophysical consequences of these mutations for channel function are summarized in [Figure 4](#fig4){ref-type="fig"} and have been described in detail in recent reviews ([@bib20], [@bib57]).Figure 4Na~V~1.7 Variants Contributing to NeuPNa~V~1.7 is the most studied ion channel with genetic association to NeuP and represents the canonical example of how variants can drive disease pathogenesis. Schematic illustrates the cardinal biophysical changes in Na~V~1.7 function associated with rare inherited (IEM and PEPD) and common NeuP states painful diabetic peripheral neuropathy (PDPN) and idiopathic small fiber neuropathy. IEM-associated variants uniquely exhibit hyperpolarized voltage of activation, whereas PEPD variants display impaired fast inactivation, which results in a persistent current in the majority of cases. Similar to PEPD, PDPN variants also demonstrate impaired fast inactivation. Small fiber neuropathy-associated variants show mixed properties, with impaired slow and fast inactivation as well as enhanced resurgent currents being described in different variants. Paroxysms of pain can be initiated by a range of triggers and are modulated by genetic and environmental factors, e.g., genetic modifiers, temperature, and metabolic state of diabetes mellitus patients ([@bib23], [@bib131]). Convergence of these factors will determine the resultant degree of primary afferent excitability, which is important in the initiation and maintenance of NeuP. In this way, clinical outcome is dependent on the basic characteristics of the mutation interacting with modifying factors, explaining why patients with identical mutations exhibit diverse clinical phenotypes and why some mutations only result in a pain phenotype upon a secondary insult.

IEM and PEPD patients carrying rare variants account for only a very small proportion of total NeuP sufferers, so how does their study advance our understanding of NeuP in general? Beyond providing insight into basic biology, familial studies have provided candidate genes to screen in common NeuP conditions. Potentially pathogenic variants in Na~V~1.7, Na~V~1.8, and Na~V~1.9 have been found in up to 17% of patients with small fiber neuropathy ([@bib64], [@bib65], [@bib93]). In a recent study of patients with diabetic peripheral neuropathy (DPN), rare Na~V~1.7 variants were found in 9% of patients with painful, but not painless DPN ([@bib23]), and in a separate study a single patient with painful DPN was found to carry a pathogenic mutation in Na~V~1.8 ([@bib86]). The biological action of these variants may be different in the two contexts. In idiopathic small fiber neuropathy (SFN), variants likely contribute directly to degeneration of intra-epidermal nerve fibers via the hyperexcitability they confer ([@bib146]), whereas in DPN the presence or absence of variants appears to impact the pain experienced in the context of fibers that have already been injured by diabetes mellitus ([@bib23]); it is also possible that such variants have an additive effect.

Given the clear role of Na~V~1.7 in inherited pain states, much effort has been invested in developing analgesic strategies targeting the channel. While still ongoing, these studies have met with mixed success. Small-molecule inhibitors have failed to deliver efficacy in phase II trials of DPN and post-herpetic neuralgia ([@bib124], [@bib147]). In contrast, one small molecule, BII074, did reach secondary endpoints and produced a degree of pain reduction for patients with trigeminal neuralgia ([@bib201]). However, the specificity of this compound for Na~V~1.7 has been questioned ([@bib122]).

Developing a specific and effective Na~V~1.7 inhibitor is beset by pharmacological challenges, but, by selecting patient cohorts based on genetics, success in clinical trials may be accelerated. In the case of rare and highly penetrant mutations, this approach has already borne fruit. Studies of carbamazepine (CBZ)-responsive IEM patients described that the drug was able to reverse the hyperpolarized activation associated with the Na~V~1.7-V400M mutant, limiting the hyper-excitability of transfected dorsal root ganglion (DRG) neurons ([@bib74]). Using the V400M variant as a seed, structural modeling and thermodynamic analysis predicted CBZ sensitivity of a second IEM variant, S241T. This prediction was subsequently confirmed *in vitro*, and the strategy was validated when two patients carrying the S241T mutations reported a reduction in pain following CBZ treatment in a small double-blind trial ([@bib79]). These findings have recently been extended to a Na~V~1.8 variant ([@bib86]). While distinct highly penetrant mutations may be rare, rational clustering of variants could provide a means to predict treatment response on an individual basis and is a realistic ambition given the increasing ease of genetic testing. In common NeuP conditions, Na~V~ inhibitors may be more effective in patients in which gain of Na~V~ channel function contributes to pathology. The anticonvulsant lacosamide is a non-selective Na~V~ channel blocker, which in early trials exhibited limited efficacy for NeuP ([@bib71]). However, by recruiting only small fiber neuropathy patients with a Na~V~1.7 variant, a recent double-blind, placebo-controlled study demonstrated that lacosamide treatment resulted in a significant reduction in pain scores and an increase in patient well being ([@bib53]). Despite these promising results, one must be cautious not to infer clinical phenotype too strongly from gene variation. Of the 13 patients with a confirmed pathogenic Na~V~1.7 variant studied by de Greef et al., seven patients did not report a reduction in pain following lacosamide ([@bib53]). Conversely, several variants in the painful DPN cohort of Blesneac and colleagues exhibited large changes in channel biophysics, but this resulted in a pain phenotype only after a secondary insult, i.e., the metabolic complications of diabetes mellitus ([@bib23]). These findings imply that dysfunction of an individual variant cannot alone predict clinical phenotype, nor will all patients carrying a certain variant respond to treatment equally. This lack of simple translation between genotype and phenotype is further supported by familial studies of rare variants, where pain onset and severity can vary drastically, even between family members carrying the same highly penetrant mutation ([@bib123]), implying a significant contribution of other genetic and environmental factors to the disease phenotype ([Figure 4](#fig4){ref-type="fig"}). Defining these interactions is a key challenge and will undoubtedly require different strategies and experimental modeling of ion channel variants and indeed any genetic differences.

Using Human Cellular Models to Study NeuP {#sec1.5}
-----------------------------------------

Advances have been made in developing new cellular models capable of investigating the interaction of gene variants with phenotype, with induced pluripotent stem cell (iPSC) technology at the forefront of recent work. This approach offers the ability to investigate the functional consequence of disease-associated variants in a human neuronal cell model that retains the entire genetic background of the patient. The benefit of iPSC technology is limited by the availability of differentiation protocols to generate physiologically accurate somatic cell types, but protocols are available to generate neurons akin to nociceptors ([@bib36]). Currently, iPSC-derived nociceptor neurons are only an approximation of their endogenous counterparts and do not replicate the full panoply of sensory neuron subtypes; however, this is an ever-evolving field. Further protocols have since been published, including for the trans-differentiation of fibroblasts directly to nociceptors, which offers a larger repertoire of sensory neuron subtypes ([@bib22], [@bib162]).

In the first experiment of its kind, IEM was modeled in patient iPSC-derived nociceptors, which exhibited many features of hyper-excitability, including reduced threshold for firing and spontaneous activity ([@bib33]). This study then neatly translated a novel Na~V~1.7 blocker, which reduced IEM iPSC-nociceptor excitability *in vitro* and resulted in a degree of pain reduction in donor patients. Although the study was small, there was a correlation between the patient iPSC lines that responded to the drug *in vitro*, and the patients who exhibited drug responsiveness ([@bib33]). While *in vitro* phenotypes for monogenic disorders have been observed ([@bib122], [@bib33]), it remains unclear whether this approach will be sensitive enough to investigate variants with small effect sizes due to the inherent variability between iPSC lines. A recent study that compared two IEM patient lines, derived from a mother and son both carrying the Na~V~1.7 S241T mutation but who exhibited stark differences in pain severity ([@bib131]), gives cause for optimism. The authors demonstrated differential excitability between the two cell lines consistent with the clinical phenotype and then, by a process of whole-exome sequencing followed by dynamic clamp studies, provided evidence of a second variant in the gene *KCNQ2* capable of modifying neuronal excitability. Such studies suggest that iPSC may enable the separation of polygenic factors underlying pain pathogenesis.

iPSC are highly amenable to CRISPR genome editing and correction of predicted pathogenic variants to generate isogenic controls is a powerful tool to causally link variants with *in vitro* phenotypes found in iPSCs ([@bib122]). This approach will be vital when investigating variants with smaller effect sizes, or variants that are highly depended on genetic background. Beyond studying genetic variants, the use of iPSC-nociceptors as screening platforms may be a substantial step forward for drug development in NeuP ([@bib33], [@bib196]). Once ion channel targets are identified, drugs can be screened for their selectivity and ability to modulate neuronal excitability ([@bib138]).

Cadaveric tissue and the potential to study genetic mutations directly in adult human DRG neurons represents an alternative *in vitro* approach. Such tissue is becoming more widely available, allowing for studies into cellular physiology and the contribution of key ionic currents to excitability ([@bib203]). Recent experiments have been undertaken to profile the electrophysiological responses of DRG neurons derived from NeuP patients ([@bib109], [@bib140]), opening up exciting avenues for experimentation. It may be unrealistic to consider obtaining DRG from patients with rare variants, but studies assessing DRG neurons from patients with Na~V~-related small fiber neuropathy/DPN will surely be possible in the future. It will also be possible to relate these findings in human DRG neurons to the wealth of sequencing data of mouse counterparts, which is beginning to illustrate the heterogeneity of gene expression and resultant functional properties between different sub-types of DRG neurons ([@bib206]). Defining how these individual neurons respond to nerve injury is an exciting near-term goal.

The Use of Model Organisms to Study the Genetics of NeuP {#sec1.6}
--------------------------------------------------------

*In silico* model systems and *in vitro* cultures of human tissues provide a novel and important way to assess the molecular interactions of any given mutation. However, as the pain experience results from integrated pathways, all the way from sensory transduction in the periphery to perception in the brain, it is critical to study this system with each level of processing intact. The development in the 1980s of transgenic and gene "knockout" mice, in combination with sequencing of the mouse genome in the early 2000s ([@bib195]) has led the advance in research into the molecular genetics of NeuP.

Assessment of NeuP in Animal Models {#sec1.7}
-----------------------------------

The assessment of NeuP in preclinical models is associated with significant challenges given the need for indirect behavioral readouts as a surrogate of the pain experience. For practical reasons, the most commonly assessed behavioral outcomes are reflex withdrawal thresholds evoked by thermal or mechanical stimuli. Preclinical animal models of traumatic nerve injury, most often the sciatic nerve or its branches, results in evoked hypersensitivity of the animal's hind limb ([@bib190], [@bib164], [@bib55], [@bib35]). This is practically useful as most animals develop marked levels of pain-like behavior to mechanical or thermal (hot or cold) stimulation; however, there are some concerns that such models neither fully mimic traumatic nerve injury, nor reflect all aspects of nerve injury seen in the clinic. The picture of preclinical research is being enriched by using animal models beyond traumatic nerve injury to more faithfully represent NeuP inducing conditions, such as chemotherapy-induced polyneuropathies, diabetic neuropathy, multiple sclerosis, or HIV-associated peripheral neuropathy. Genetics has also been useful in developing improved models of NeuP. An example is the use of genetic mouse and rat models of diabetes which produce a slowly progressive diabetic polyneuropathy rather than the severe, acute model of streptozotocin-induced neuropathy, which is hindered by the direct neurotoxic effects of this compound ([@bib3], [@bib97]).

In humans, NeuP commonly presents with a complex combination of different sensory signs and symptoms. Patients with traumatic peripheral nerve injury for example show thermal hypersensitivity (increase in cold and/or heat pain sensitivity) in around 39% of cases, but only 8% of patients with polyneuropathy have this symptom ([@bib118]). Mechanical hypersensitivity is seen in a third of NeuP patients with mixed etiologies; specifically blunt pressure is present in 36% of patients, pinprick sensitivity in 29%, and dynamic mechanical allodynia in 20% of those studied ([@bib118]). Furthermore, evoked hypersensitivity does not correlate well with reported pain severity ([@bib12]), except in certain conditions, such as post-herpetic neuralgia ([@bib157]). Thus, in contrast to mice, hypersensitivity (sensory gain) is not always present in patients and means we should not rely on any single outcome measure to inform us of the full presentation of NeuP in either species.

To address the issue of non-evoked pain in preclinical models, ethologically relevant behavioral assessment has been suggested as an indicator of ongoing pain-like behavior ([@bib152]). An example in mice is burrowing behavior, which is impaired in different models of toxic neuropathies ([@bib80], [@bib92]), although in nerve-injured animals this behavior (in addition to animal gait and grooming measures) does not correlate well with mechanical hypersensitivity ([@bib4], [@bib133]). Conditioned place-preference/avoidance provides an external measure of internal rewarding/aversive perception ([@bib50]) and may help to separate the sensory and affective components of the pain experience. Neuropathic animals, but not controls, prefer a chamber paired with administration of an analgesic drug, suggesting the relief of an ongoing aversive state ([@bib177], [@bib104]). *In vivo* calcium imaging in awake, behaving animals was recently used to show activity in an amygdala brain circuit driven by innocuous stimuli in neuropathic animals; when this circuit was silenced, mice failed to develop conditioned place-avoidance but still displayed hypersensitive responses to evoked stimuli ([@bib45]). Other cognitive behavioral assays such as thigmotaxis in an open arena, elevated plus-maze, and light-dark box preference are useful in animal studies of comorbidities of NeuP such as anxiety ([@bib167]).

Defining the Molecular Pathways that Create NeuP {#sec1.8}
------------------------------------------------

Transcriptional profiling obtained from DRG has revealed the sheer breadth of gene regulation after neuropathic injury ([@bib14], [@bib41]) and demonstrated important contributions from non-neuronal glial and infiltrating immune cells ([@bib44], [@bib112]). A recent comparison of mouse and human DRG transcriptomes revealed highly conserved enrichment of transcription factors and axonal trafficking of mRNA providing strong external validity in the use of mice for drug-protein interactions ([@bib149]). Conversely, regional differences in sensory neuron gene expression, such as between spinal and trigeminal sensory ganglion, could also be exploited for targeted drug discovery ([@bib111]). Beyond mRNA, the extensive non-coding transcriptome may add a further layer of complexity to pain regulation ([@bib17], [@bib205]).

Sensory ganglia gene expression can also provide insight into analgesic mechanisms and potential novel analgesic therapies ([@bib184]). For example, variable DRG carbonic anhydrase-8 (CA8) expression appears to regulate nociception in mice through inhibiting intracellular signaling and nerve growth factor (NGF) responses ([@bib107], [@bib207]). Accordingly, DRG transduction of CA8 by viral gene transfer, associated with selective CA8 expression in small and medium sensory neurons, produced profound analgesia in mouse models of NeuP. Targeting sensory ganglia using gene transfer (CA8 or otherwise) may therefore represent a future therapeutic approach.

As genetic markers for subpopulations of peripheral sensory neurons and spinal cord dorsal horn neurons become better defined ([@bib185], [@bib108], [@bib42], [@bib87], [@bib37]), it allows for the ever more refined targeting of specific cells involved to pain transduction. Single-cell gene profiling has been applied to tissues from neuropathy models to reveal the heterogeneity of the injury response in regeneration associated genes and cell death pathways among sensory neuron subsets ([@bib91]), and expression profiling by ribosome affinity purification has revealed novel signaling pathways during chemotherapy-induced peripheral neuropathy in genetically defined sensory neurons ([@bib126]). Reporter mice conditionally expressing recombinases such as Cre, Flp, Dre, and more recently VIKA ([@bib100]) can then be used to achieve highly defined expression of chemogenetic and optogenetic tools ([@bib7], [@bib130]). Used in combination with sophisticated electrophysiological preparations ([@bib81]), the identification of unique cell subsets in the dorsal horn, in particular, has revealed novel facets of the mechanisms of spinal gain-of-function phenomena, including "wind-up" of nociceptive inputs ([@bib82]) and the gate-control of innocuous mechanical stimuli evoking pain ([@bib204]).

Genetic Homogeneity of Animal Models: A Help or a Hindrance? {#sec1.9}
------------------------------------------------------------

The display of pain behaviors in response to any given NeuP model are generally consistent between mice of the same strain but can differ markedly *between* strains ([@bib132]). The use of genetically homogeneous inbred mice for the majority of pain research has been based on the assumption that a defined genetic background will be a less variable and more reliable model than genetically heterogeneous outbred mice ([@bib68]). Until recently, however, little empirical evidence existed to back up this assumption ([@bib69]). A recent comprehensive literature review revealed no difference in experimental outcomes between inbred and outbred lines. Given the same sample size, outbred mice are phenotypically as stable as inbred strains ([@bib183]). Thus, genetically diverse outbred models should help avoid strain-specific responses and complement the study of heritable diseases across a diverse population.

In addition, inbred strains, such as C57BL/6, are commonly used to provide a homogeneous genetic background with which to test the effects of a particular gene variant on a given phenotype ([@bib200]). However, the choice of genetic background can have a dramatic effect on the allele phenotype, often attributed to background-specific modifier genes or epigenetic modifications ([@bib168]). One way to control for this issue is to repeat the study in at least two different backgrounds ([@bib110]). When genetic mutations are not stable enough to give closely matching phenotypes across strains of mice, it becomes difficult to predict their penetrance between species or in a population of patients. In common with GWAS studies, more complex algorithms to define genetic interactions and their relative importance to phenotype will undoubtedly improve our understanding of polygenic factors in animal models ([@bib54], [@bib34]).

Genetic variation also exists between mouse strains in axonal regeneration ([@bib141], [@bib179]). The majority of preclinical nerve injury models are designed to restrict axonal regrowth by transection or ligation of part of a peripheral nerve, leading to a permanent, partial denervation ([@bib166], [@bib121]). Recent evidence also points to a failure of damaged axons to successfully degenerate and re-innervate as a driver of persistent pain ([@bib198], [@bib51]). Strain differences in the intrinsic neuronal and immune response to injury may also impact upon the development and/or resolution of the chronic pain state. Potential biases in strain-specific behavior may be overcome by use of multiple inbred strains in a single factorial design that allows a well-powered exploration of genetic heterogeneity without substantially increasing sample size ([@bib70]). Alternatively, a sample of mice from a heterogeneous population such as the Diversity Outbred population may avoid the idiosyncrasies of inbred strains ([@bib183]). The precision and allelic diversity of the outbred population greatly exceeds conventional inbred mouse strain crosses. At larger sample sizes, such populations can be used directly for precise genetic mapping of the variability in response ([@bib150]).

The discovery of sex-specific effects controlling mouse NeuP development ([@bib171], [@bib178]) has highlighted the imbalance between sexes in preclinical animal models ([@bib43]). Sex-specific immune function has been linked to variations in pain sensitivity due to hormonal changes associated with the menstrual cycle and pregnancy ([@bib155]), or opioid analgesic efficacy ([@bib156]), and lend a mechanistic explanation to what has been suspected clinically for years ([@bib16]). Sex differences in the response to a neuropathic injury may be additionally encoded in the immune system ([@bib112]). This raises interesting questions concerning expression profiling in chronic pain studies, since changes in gene expression could represent bona fide transcriptional responses of pain circuitry, or indicate immune cell recruitment after injury ([@bib44], [@bib112], [@bib51]). There are also key strain-related differences in immune function that relate to known NeuP pathways. C57BL/6 mice showed the highest vulnerability to mechanical hypersensitivity after partial nerve ligation ([@bib96]); in contrast, mice of the C3H/He strain were more resistant, which correlated with more anti-inflammatory macrophages (M2) in the DRG ([@bib96]). The bias of the C57BL/6 strain to Th1-type inflammatory responses ([@bib194]) could therefore have significant bearing on neuropathies with a strong immune component.

Reaching across the Evolutionary Divide {#sec1.10}
---------------------------------------

When considering an animal model, it is tempting to opt for fidelity, i.e., the overall likeness of a model to the human disease. Toward this end, attempts have been made to improve the relevance of preclinical models of chemotherapy-induced NeuP by climbing the evolutionary ladder from rodents to non-human primates ([@bib83]). In comparison to rats, for example, macaques reportedly show a pharmacological response closer to that of patients following oxaliplatin treatment ([@bib165]), with brain imaging revealing *de novo* activity in the somatosensory and insular cortices in response to cold stimulation only in treated animals ([@bib135]), similar to noxious thermal stimulation in patients undergoing oxaliplatin treatment ([@bib25]).

It is the principle of discrimination---i.e., the replication of a specific phenotype in disease modeling ([@bib158])---that guides the replacement of higher-order species, such as monkeys and rodents, with lower-order species including invertebrates ([@bib176]). Full genome sequence assembly of *Drosophila melanogaster* (fruit fly), *Caenorhabditis elegans* (nematode worm), and *Danio rerio* (zebrafish) have allowed these organisms to play an important role in investigating conserved human disease genes and assisting drug development, despite fundamental differences in morphology and organ systems ([@bib172]). One reason for this is that in general the function of genes, once defined, do not vary; there may be duplication and other forms of molecular evolution, but important pathways and the genes within them are by and large well conserved once their roles are established ([@bib106]). It is also useful to consider the reasons for the first action potential in the sensory pathway: to identify and seek out the "good" (i.e., food and a healthy environment) or conversely to determine and avoid the "bad" (i.e., predation and toxic environments), the latter resulting in the creation of nociception and pain. Therefore, biology has processed noxious stimuli from the very earliest electrically excitable impulses ([@bib169], [@bib170]), meaning that both the pain phenotype and the genes that create it appear to be extremely well conserved across the animal phyla. Although we are a long way from attributing a perceptive quality such as "pain" to lower organisms, the use of forward genetics has led to the discovery of gene families that control nociception and more recent data hinting at the potential evolutionary conservation of neuropathic mechanisms ([@bib103]).

### Fruit Fly {#sec1.10.1}

When it comes to rapid turnaround forward genetics, few organisms have made more contributions to genetic screening than the fruit fly, *Drosophila melanogaster.* The archetypal nociceptor family transient receptor potential (TRP) channels were first identified phenotypically in flies in the 1960s for their role in sensory perception of light ([@bib46]), and the genetic tools available in fly genetics allowed cloning of the first TRP channel in the 1980s ([@bib134]). The first application of fruit fly genetics to nociception was in a study by [@bib181], who described a heat assay in fly larvae, where they exhibit a rapid rolling escape response when touched with a probe heated to 46°C.

Beyond acute nociception, the fly somatosensory system displays properties of sensitization. Initial assays focused on sensitization evoked by inflammation ([@bib10], [@bib11]); however, models of nerve injury are now being developed ([@bib103]). Chemotherapeutic agents can sensitize larvae to mechanical and heat stimuli ([@bib24], [@bib29], [@bib84]). *Drosophila* larvae also exhibit thermal hypersensitivity following high-sugar diet or through genetic ablation of insulin signaling, and this may help in the understanding of diabetic neuropathy ([@bib95]).

While informative with respect to rapid sensitization, fly larval paradigms are transient by nature and cannot be used to investigate chronic sensitization. Instead, adult flies have been used for this purpose. After removal of a leg, adult fruit flies display enhanced thermal nociception escape responses and exhibit a heightened state of vigilance ([@bib103]). This disease state caused by nerve injury develops after a loss of GABAergic inhibition in the ventral nerve cord ([@bib103]), analogous to the vertebrate spinal cord. This mechanism appears to be the fly equivalent of spinal disinhibition that occurs in mice after nerve peripheral nerve injury ([@bib120]). These findings establish that flies enter a NeuP-like state after injury that involves permanent central disinhibition, suggestive of chronic NeuP. A brief summary of fly paradigms is shown in [Figure 1](#fig1){ref-type="fig"}.

### Worms and Fish {#sec1.10.2}

Modeling of individual characteristics and complications of peripheral neuropathies in a reductionist approach may help to define the core machinery involved in NeuP. Nematodes and zebrafish possess the neural circuitry capable of nociception, behavioral avoidance, and signal modulation ([@bib38]) making them powerful models for high-throughput and genetic control for novel analgesic drug discovery ([@bib62]). Glucose-induced neurotoxicity in zebrafish was used to demonstrate the beneficial effect of matrix metalloproteinase (MMP) inhibition, which paralleled findings in mice ([@bib191]), suggesting the conservation of this mechanism of metabolic neuropathy. Overexpression of gain-of-function mutations of Na~V~1.7 in zebrafish sensory neurons led to decreased small fiber density and increased sensitivity to temperature changes ([@bib60]), recapitulating the hallmarks of small fiber neuropathy in patients ([@bib90]).

Reverse genetics in the nematode is enhancing our understanding of hereditary peripheral neuropathies. Deposits of misfolded transthyretin (TTR) protein around sensory and autonomic nerves, characterize familial amyloid polyneuropathy with NeuP being an early symptom ([@bib163]). Introduction of a patient TTR variant to the nematode led to a loss of noxious heat responses, likely due to the proteotoxicity of TTR oligomers ([@bib116]). Mutations in serine palmitoyltransferase (SPT) cause hereditary sensory and autonomic neuropathy type 1 in patients, via accumulation of neurotoxic deoxy-sphingolipids ([@bib76]). Insertion of the equivalent SPT mutation into the nematode led to defects in neuronal polarization and vesicular trafficking ([@bib49]).

Comorbidities of NeuP {#sec1.11}
---------------------

Beyond the seriously debilitating effects of chronic pain, the presence of multiple comorbidities, including anxiety, depression, and sleep disorders further complicate patient difficulties ([@bib52], [@bib105], [@bib148]). For NeuP, most work has been performed on depression ([@bib94], [@bib59], [@bib15]). Within the general population there is an incidence of depression throughout life of about 16% ([@bib30]), which compares to a rate of 50% ([@bib13]) in NeuP patients, suggesting strong neurochemical commonalities. Recent data suggest that chronic pain and depression may share common genetic and cellular causes, including neuro-inflammation within the CNS ([@bib115]), dysregulation of neurotrophic factors and neuropeptides ([@bib59], [@bib94]), as well as excessive glutamatergic, reduced GABAergic, and impaired endocannabinoid signaling ([@bib94]). Microglia and astrocytes are resident non-neuronal cells of the brain and spinal cord that are important endogenous mediators of neuro-inflammation. Activation of microglia in the amygdala ([@bib31]) and of astrocytes in the amygdala and periaqueductal gray (PAG) ([@bib139], [@bib31]) is seen in neuropathic animals with comorbid symptoms of depression.

Anxiety in response to acute pain is responsible for hypervigilance as well as other components of the fight or flight response, and in this context it is protective. However, in NeuP these responses become chronic and can be detrimental to overall health, with widespread immune and neural dysfunction contributing to a vicious cycle of ongoing anxiety and musculoskeletal pain ([@bib6]). It has been shown that anxiety levels in diabetic neuropathy patients with NeuP are significantly higher than in subjects without pain ([@bib167]), and that NeuP presents with maximal levels of anxiety ([@bib8]).

Research in animals suggests that anxiety is driven by ongoing painful input over the medium- to long-term rather than prior anxiety being a driver toward neuropathic hypersensitivity ([@bib167]). However, anxiety can modulate pain in the short term; for example, stress-induced analgesia, which is an in-built mammalian pain suppression response that occurs during or immediately following exposure to a stressful or frightening stimulus ([@bib32]). Therefore, measurements of anxiety levels should not be taken as a proxy for pain, unless the condition initiating the pain is adequately defined, again demonstrating the need for careful phenotyping.

Sleep disturbance is common in NeuP with estimates in chronic pain patients ranging between 50% and 80% ([@bib40]). Interestingly, the link between sleep and pain is bi-directional, with lack of sleep amplifying pain perception ([@bib40], [@bib2]). It will therefore be of interest to understand whether therapies focused on improving sleep hygiene will also improve NeuP symptoms. Sleep as a comorbidity may also be considered in relation to analgesic treatment choice for NeuP. Gabapentin/Pregabalin have been shown to improve sleep latency and depth in diabetic neuropathy ([@bib5], [@bib159]), while conversely Duloxetine can enhance sleep fragmentation ([@bib27]).

Despite the clear associations and high prevalence of these conditions as comorbidities of NeuP, there have so far been no studies demonstrating shared genetic architecture between NeuP and depression, anxiety, or sleep disorders. However, insights can be gained from the few studies that have been conducted in chronic pain in general. A twins study, for example, found a genetic correlation of 0.56 between pain and depression and of 0.69 between pain and sleep disorders ([@bib77]). Similarly, a family-based study found a strong genetic correlation between chronic pain and depression (r = 0.51) ([@bib125]). Polygenic risk scores for depression were associated with chronic pain in the same cohort and in independent samples, but not vice versa ([@bib125]). GWAS studies relating to depression, anxiety, and sleep disorders have provided some insight into the potential pleiotropic effect of the genes that have been found to be associated with NeuP in patients ([@bib188]) ([Figure 3](#fig3){ref-type="fig"}). For example, *HLA*-*B* is associated with feeling miserable and nervous ([@bib137]), *HLA-DQB1* is associated with narcolepsy ([@bib85]) and feeling nervous or worried ([@bib137]), and *PKRCA* is associated with neuroticism ([@bib136]). Further work is required to uncover the genetic overlap between these comorbidities and NeuP.

Conclusions {#sec1.12}
-----------

NeuP is diverse in its clinical phenotype, molecular mechanisms, and the types of injury that precipitate it. This diversity, in common with most chronic disease, is due to a mixture of environmental and genetic influences. In order to better treat this disparate set of pathologies, we urgently need to develop better means to stratify NeuP into accurately quantified and mechanistically relevant sub-groups (for instance, in terms of distinct sensory profiles) both in humans and in experimental animals. Only when we can accurately stratify NeuP will we be able to use whole-genome screens to define individual and shared molecular mechanisms within these populations. Such stratification will enable construction of novel therapies and better targeting of existing therapies for each chronic pain phenotype in turn. In some cases, such treatments may encompass many neuropathic etiologies; for instance, selectively reducing sodium current in peripheral nociceptors holds much promise for peripheral NeuP disorders. Clearly, the environment plays an important role in amplifying or diminishing these signaling cascades, and understanding these factors will be crucial not only for diagnosis but also for treatment. We have already made huge advances toward this goal: cross-comparing species has aided the definition of apex signaling cascades, and the use of model organisms (chiefly rodents) has been invaluable in the development of our understanding of pain processing from molecules to neural circuits and how this might be modulated with drugs or other therapies. New molecular techniques are currently turbocharging these advances: next-generation sequencing is now being applied to large clinical populations, and CRISPR technology allows rapid functional validation of identified targets in model organisms. It is our firm belief that we are poised to make a number of fundamental advances, which should aid the treatment of neuropathic and indeed other types of chronic pain. To do so, we need to continue to define the genetic architecture of NeuP, in both patients and model organisms, with the aspiration to move beyond opiates and develop new efficacious and non-addictive analgesics.
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